Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Pharmacyclics
Pharmacyclics
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Rentschler Biopharma appoints Patrick Cushing as VP Operations for US subsidiary
The novel position will require Dr Cushing to manager operations at the Miford, MA facility in the US
Making the most of each cell: single-use perfusion in biopharma processing
GEA kytero perfusion disk stack separators are pioneering the time- and cost-efficient harvesting of pharmaceutical proteins from cells and facilitating continuous processing,...
Johnson & Johnson submits regulatory application for Tremfya to the European Medicines Agency
The submission included data from the Phase 3 QUASAR programme in ulcerative colitis and the Phase 3 GALAXI programme in Crohn’s disease, which each achieved their primary...
Amolyt receives FDA fast track designation for hypoparathyroidism drug
The therapeutic has been awarded the fast track designation owing to the Phase III Calypso trial, which showed promising efficacy and safety features
Indian government bans three medicines owing to health risks
Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Finance
AbbVie to purchase Pharmacyclics for US$21bn
Gains access to cancer treatment Imbruvica
WuXi subsidiary in deal with Pharmacyclics
Supply arrangement follows approval of Imbruvica by US FDA
Manufacturing
Catalent to supply cancer drug capsules for commercial supply to Pharmacyclics
Following approval by the US Food and Drug Administration for the treatment of mantle cell lymphoma
You need to be a subscriber to read this article.
Click here
to find out more.
Regulatory
Blood cancers – ibrutinib
There is a need for new treatment options for patients whose treated chronic lymphocytic leukaemia or other B-cell malignancy has relapsed, or who do not respond to existing therapies
Subscribe now